What You Should Know:
– Promise Bio, a startup transforming immune-mediated disease treatment with advanced precision medicine solutions, today announced its emergence from stealth with an $8.3 million seed investment.
– This funding will accelerate the development of Promise Bio’s computational platform, which uses epiproteomics and artificial intelligence to predict patient treatment responses and support drug research and development.
Revolutionizing Immune-Mediated Disease Management through Epiproteomics and AI
Promise Bio is a trailblazer in precision medicine, advancing the management of immune-mediated diseases with an innovative focus on epiproteomics and artificial intelligence (AI). Leveraging groundbreaking research from the Weizmann Institute of Science, the company’s proprietary technology enables large-scale profiling of post-translational modifications (PTMs) in proteins. This platform identifies disease mechanisms, customizes therapies, and uncovers novel drug targets with unparalleled precision.
At the core of Promise Bio’s success is its proprietary PROMISE (Protein Modification Integrated Search Engine) platform, developed by Co-Founder & CTO Dr. Assaf Kacen. This cutting-edge system, based on foundational research conducted in Prof. Yifat Merbl’s lab at the Weizmann Institute and published in Nature Biotechnology in 2023, allows high-throughput profiling of dozens of PTMs using mass spectrometry. The platform eliminates the need for customized chemical enrichment or additional lab procedures, significantly streamlining the analysis of PTMs and accelerating biomedical discovery.
Strategic partnerships with two leading biopharmaceutical companies enhance Promise Bio’s capacity to integrate its technology into global drug development pipelines. These alliances provide:
- Financial support, ensuring sustained innovation.
- Industry expertise, enabling effective translation of research into clinical applications.
- Access to global networks, fostering collaboration and expanding the reach of precision medicine solutions.
By building the world’s largest PTM database, Promise Bio is creating an indispensable resource for medical breakthroughs while addressing pressing clinical challenges in immune-mediated diseases.
Addressing the unmet need for precision treatments, Promise Bio targets the current inefficiencies in autoimmune disease therapies, where only 30–40% of patients achieve significant remission. The company emphasizes data-driven approaches to eliminate the trial-and-error treatment paradigm. Its PROMISE platform focuses not only on protein levels but also on the modifications proteins undergo after formation, delivering actionable insights for tailored interventions.
“Proteins are the building blocks of the human body, and understanding their post-formation changes is key to solving the challenges in immune-mediated diseases,” explained Ronel Veksler, Co-Founder & CEO. With this vision, Promise Bio is poised to transform the future of precision medicine.
